For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

Novartis (NOVN: VX) has reported new data showing that its investigational BTK inhibitor, remibrutinib, significantly ...

The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

and relapsing multiple sclerosis], and remibrutinib [chronic spontaneous urticaria and hidradenitis suppurativa]. In my opinion, these experimental drugs, as well as those already approved by the ...

Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...